8-K: MyMD Pharmaceuticals Secures $7 Million Investment from PharmaCyte Biotech

PharmaCyte Biotech has made a $7 million strategic investment in MyMD Pharmaceuticals, a biopharmaceutical company focused on inflammatory diseases.

Summary

• PharmaCyte Biotech has invested $7 million in MyMD Pharmaceuticals.
• The investment includes the purchase of MyMD's Series G Convertible Preferred Stock, warrants to purchase common stock with a five-year term, and warrants to purchase common stock with an 18-month term.
• The closing of the transaction is expected on May 23, 2024, subject to customary closing conditions.
• The preferred shares are convertible into common stock at an initial price of $1.816, subject to adjustments.
• MyMD has the option to redeem the preferred shares in cash at a premium.
• PharmaCyte will be entitled to dividends of 10% per annum, compounded monthly, payable in cash or MyMD common shares.
• Upon a triggering event, the dividend rate increases to 15% per annum.
• The warrants are exercisable immediately at $1.816 per share and expire in either 18 months or 5 years.
• The exercise price of the warrants is subject to adjustments.
• MyMD is required to file a resale registration statement with the SEC within 30 days after closing to register 200% of the conversion shares and warrant shares.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a strategic investment and potential for future collaboration. The terms of the investment are favorable for the investor, but there are also some risks and limitations mentioned. Overall, the sentiment is moderately positive.

Positives

• PharmaCyte's investment provides MyMD with capital to advance its clinical studies.
• The investment is a strategic move for PharmaCyte to create value through external opportunities.
• MyMD's approach to inflammation addresses significant unmet medical needs.
• PharmaCyte has the right to nominate one individual to serve on MyMD's board of directors until the Company no longer beneficially owns 20% of MyMD's common stock on an as-converted basis.
• PharmaCyte has the right to participate in future sales of MyMD's equity and equity-linked securities until the second anniversary of the Closing or the date on which no MyMD Preferred Shares remain outstanding, whichever is earlier.

Negatives

• MyMD's ability to settle conversions and make dividend make-whole payments by issuing MyMD Common Shares is subject to certain limitations.
• MyMD is subject to certain affirmative and negative covenants regarding the incurrence of indebtedness, the existence of liens, the repayment of indebtedness, the payment of cash in respect of dividends (other than dividends pursuant to the Certificate of Designations), distributions or redemptions, and the transfer of assets, among other matters.

Risks

• The closing of the transaction is subject to customary closing conditions.
• MyMD's ability to settle conversions and make dividend make-whole payments by issuing MyMD Common Shares is subject to certain limitations.
• The conversion price and exercise price are subject to adjustments, which could impact the value of the investment.
• There are certain triggering events that could lead to a redemption of the preferred shares at a premium.
• MyMD is subject to certain affirmative and negative covenants regarding the incurrence of indebtedness, the existence of liens, the repayment of indebtedness, the payment of cash in respect of dividends (other than dividends pursuant to the Certificate of Designations), distributions or redemptions, and the transfer of assets, among other matters.

Future Outlook

PharmaCyte anticipates continuing to seek out additional opportunities which they hope will ultimately result in marked value for PharmaCyte and its stockholders. MyMD is actively preparing to continue its clinical studies in its lead product candidate, MYMD-1.

Management Comments

• Chris Chapman, M.D., president and chief medical officer of MyMD, stated, 'This investment comes at an important inflection point for MyMD, as we are actively preparing to continue our clinical studies in our lead product candidate, MYMD-1, following our positive data from our Phase 2 trial in sarcopenia. We are looking forward to potential collaboration with PharmaCyte, as its management and board have extensive experience in the public biotechnology markets. We believe that this strategic investment will also provide helpful insight as we continue to develop our technology.'
• Dr. Michael Abecassis, a member of PharmaCyte's Board of Directors, said, 'Our investment in MyMD solidifies our commitment to our previously announced corporate strategy to identify significant outside opportunities where we can create value both through cash investment and our own expertise. MyMDs approach to inflammation is unlike what is currently available and addresses significant unmet medical needs in this category. We believe we can contribute to its continued development, and we look forward to further collaboration and sharing in MyMDs success. We anticipate continuing to seek out additional opportunities which we hope will ultimately result in marked value for PharmaCyte and its stockholders.'

Industry Context

This investment reflects a trend of pharmaceutical companies seeking strategic partnerships and investments to expand their pipelines and leverage external expertise. It also highlights the growing interest in novel therapies for inflammatory diseases and age-related conditions.

Comparison to Industry Standards

• The structure of the investment, including convertible preferred stock and warrants, is a common approach in biotech financing.
• The dividend rate of 10% per annum on the preferred shares is relatively high, reflecting the risk associated with early-stage biotech investments.
• The full ratchet price-based adjustment on the warrants is a strong protection for the investor, ensuring that the exercise price will be reduced if MyMD issues shares at a lower price.
• The requirement for MyMD to file a resale registration statement within 30 days is a standard provision in private placements, providing liquidity for the investors.
• The right to nominate a board member is a common feature for strategic investors, giving PharmaCyte influence over MyMD's direction.

Stakeholder Impact

• Shareholders of PharmaCyte may benefit from the potential value creation through this strategic investment.
• Shareholders of MyMD may benefit from the additional funding and potential collaboration with PharmaCyte.
• Employees of both companies may see new opportunities for growth and development.
• Customers of MyMD may benefit from the continued development of novel therapies.

Next Steps

• The closing of the transaction is expected on May 23, 2024.
• MyMD is expected to file a resale registration statement with the SEC within 30 days after closing.
• PharmaCyte will likely seek additional strategic investment opportunities.
• MyMD will continue its clinical studies in its lead product candidate, MYMD-1.

Key Dates

Keywords

investment, biopharmaceutical, preferred stock, warrants, common stock, registration rights, inflammation, clinical trials, strategic investment, conversion, redemption